Effects of radix adenophorae and cyclosporine A on an OVA-induced murine model of asthma by suppressing to T cells activity, eosinophilia, and bronchial hyperresponsiveness

Abstract

The present study is performed to investigate the inhibitory effects of Radix Adenophorae extract (RAE) on ovalbumin-induced asthma murine model. To study the anti-inflammatory and antiasthmatic effects of RAE, we examined the development of pulmonary eosinophilic inflammation and inhibitory effects of T cells in murine by RAE and cyclosporine A (CsA). We examined determination of airway hyperresponsiveness, flow cytometric analysis (FACS), enzyme-linked immunosorbent assay (ELISA), quantitative real time (PCR), hematoxylin-eosin staining, and Masson trichrome staining in lung tissue, lung weight, total cells, and eosinophil numbers in lung tissue. We demonstrated how RAE suppressed development on inflammation and decreased airway damage.

Figure 1

Effects of RAE and CsA on methacholine-induced AHR in the sensitization (NM: normal C57BL/6 mice; CT: OVA-induced asthma mice (control); CsA: OVA-induced asthma mice treated with cyclosporine A (10 mg/kg); RAE 450 mg/kg: OVA-induced asthma mice treated with RAE (450 mg/kg); RAE 45 mg/kg: OVA-induced asthma mice treated with RAE (45 mg/kg)).

Figure 2

Effect of RAE on histology of lung tissue (H&E and Masson trichrome staining) in lung tissues of OVA-induced asthma murine ((a): normal C57BL/6 mice; (b): OVA-induced asthma mice (Control 1); (c): OVA-induced asthma mice (Control 2); (d): OVA-induced asthma mice treated with cyclosporine A (10 mg/kg); (e): OVA-induced asthma mice treated with RAE (450 mg/kg); (f): OVA-induced asthma mice treated with RAE (45 mg/kg)).

Figure 3

Effect of RAE on immunohistochemistry of lung tissue (Congo red stain) in lung tissues of OVA-induced asthma murine ((a): normal C57bl/6 mice; (b) and (c): OVA-induced asthma mice (control); (d): OVA-induced asthma mice treated with cyclosporine A (10 mg/kg); (e): OVA-induced asthma mice treated with RAE (450 mg/kg); (f): OVA-induced asthma mice treated with RAE (45 mg/kg)).

Figure 4

Effects of RAE on lung weights and total lung cells in OVA-induced asthma murine (NM: normal C57BL/6 mice; CT: OVA-induced asthma mice (control); CsA: OVA-induced asthma mice treated with cyclosporine A (10 mg/kg); RAE 450 mg/kg: OVA-induced asthma mice treated with RAE (450 mg/kg); RAE 45 mg/kg: OVA-induced asthma mice treated with RAE (45 mg/kg)).

Figure 5

Effect of RAE on CD3e⁻/CCR3⁺ population in lung tissues of OVA-induced asthma murine (NM: normal C57BL/6 mice; CT: OVA-induced asthma mice (control); CsA: OVA-induced asthma mice treated with cyclosporine A (10 mg/kg); RAE 450 mg/kg: OVA-induced asthma mice treated with RAE (450 mg/kg); RAE 45 mg/kg: OVA-induced asthma mice treated with RAE (45 mg/kg)).

Figure 6

Effects of RAE on CD4⁺/CD8⁻, GR-1⁺/CD11b⁺, IgE⁺/B220⁺, and CD3e⁺/CD69⁺ cells absolute number in lung and spleen tissues of OVA-induced asthma murine (NM: normal C57BL/6 mice; CT: OVA-induced asthma mice (control); CsA: OVA-induced asthma mice treated with cyclosporine A (10 mg/kg); RAE 450 mg/kg: OVA-induced asthma mice treated with RAE (450 mg/kg); RAE 45 mg/kg: OVA-induced asthma mice treated with RAE (45 mg/kg)).

Figure 7

Effect of RAE on cytokines, immunoglobulin E levels in BALF and histamine release in serum (NM: normal C57BL/6 mice; CT: OVA-induced asthma mice (control); CsA: OVA-induced asthma mice treated with cyclosporine A (10 mg/kg); RAE 450 mg/kg: OVA-induced asthma mice treated with RAE (450 mg/kg); RAE 450 mg/kg: OVA-induced asthma mice treated with RAE (450 mg/kg)).